XML 145 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Segmentation of key figures (Details 2) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Interest income $ 379 $ 71 $ 91
Impairment charges and fair value gains on financial assets, net (260) 38 335
Equity-based compensation of Novartis equity plans (1,048) (979) (958)
Restructuring provision [member]      
Disclosure of operating segments [line items]      
Additions to restructuring provisions (1,368) (328) (354)
Right-of-use assets [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (300) (318) (330)
Impairment loss (reversal of impairment loss) recognised in profit or loss (3)    
Intangible assets and goodwill [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (3,982) (3,903) (3,462)
Impairment loss (reversal of impairment loss) recognised in profit or loss (1,326) (403) (914)
Property, plant and equipment [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (1,163) (1,208) (1,318)
Impairment loss (reversal of impairment loss) recognised in profit or loss (407) (281) (440)
Innovative Medicines      
Disclosure of operating segments [line items]      
Impairment charges and fair value gains on financial assets, net (134) 43 153
Equity-based compensation of Novartis equity plans (706) (721) (714)
Innovative Medicines | Restructuring provision [member]      
Disclosure of operating segments [line items]      
Additions to restructuring provisions (1,069) (240) (217)
Innovative Medicines | Right-of-use assets [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (252) (265) (273)
Impairment loss (reversal of impairment loss) recognised in profit or loss (3)    
Innovative Medicines | Intangible assets and goodwill [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (3,728) (3,638) (3,080)
Impairment loss (reversal of impairment loss) recognised in profit or loss (1,299) (367) (768)
Innovative Medicines | Property, plant and equipment [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (837) (859) (912)
Impairment loss (reversal of impairment loss) recognised in profit or loss (407) (271) (324)
Sandoz      
Disclosure of operating segments [line items]      
Equity-based compensation of Novartis equity plans (62) (65) (64)
Sandoz | Restructuring provision [member]      
Disclosure of operating segments [line items]      
Additions to restructuring provisions (40) (62) (98)
Sandoz | Right-of-use assets [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (33) (39) (41)
Sandoz | Intangible assets and goodwill [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (222) (238) (370)
Impairment loss (reversal of impairment loss) recognised in profit or loss (25) (28) (141)
Sandoz | Property, plant and equipment [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (204) (210) (282)
Impairment loss (reversal of impairment loss) recognised in profit or loss   (9) (116)
Corporate      
Disclosure of operating segments [line items]      
Impairment charges and fair value gains on financial assets, net (126) (5) 182
Equity-based compensation of Novartis equity plans (280) (193) (180)
Corporate | Restructuring provision [member]      
Disclosure of operating segments [line items]      
Additions to restructuring provisions (259) (26) (39)
Corporate | Right-of-use assets [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (15) (14) (16)
Corporate | Intangible assets and goodwill [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense (32) (27) (12)
Impairment loss (reversal of impairment loss) recognised in profit or loss (2) (8) (5)
Corporate | Property, plant and equipment [member]      
Disclosure of operating segments [line items]      
Depreciation and amortisation expense $ (122) (139) $ (124)
Impairment loss (reversal of impairment loss) recognised in profit or loss   $ (1)